Company Overview
SkyDance Vascular, Inc., established in 2017, focuses on innovative medical equipment manufacturing, particularly in Peripheral Intravenous Catheter (PIVC) technology. Headquartered at 1104 Nassau Street, Suite 107, Delray Beach, FL 33483, the company can be reached via phone at 561-573-5360 or email at info@skydancevascular.com. Additional details are available on their [official website](https://www.skydancevascular.com).
Products and Innovations
SkyDance Vascular's flagship product is the OspreyIV catheter delivery system, which represents a significant advancement in peripheral vascular access, highlighted by its successful FDA 510(k) clearance. The company's innovations focus on minimizing the complications associated with traditional catheter designs and include:
- Bevel Only Technique: This reduces the risk of phlebitis and infiltration by preventing the needle from penetrating beyond the initial entry.
- Skin Avoidance Technology: Ensures the catheter avoids skin contact, thereby lowering infection risks.
- Passive Needle Retraction: The needle automatically retracts to prevent injury to clinicians.
- Contoured Directional Flow: Enhances fluid delivery efficiency and reduces chemical/mechanical damage.
In September 2023, they achieved FDA clearance for their OspreyV2-20, further demonstrating their commitment to advancing vascular access solutions.
Team Composition
SkyDance Vascular's leadership is formed by seasoned professionals with extensive experience in medical devices, enterprise software, and vascular access:
- Bill Bold, CEO, with over 30 years in the medical device industry.
- Mike Anstett, Chief Clinical Officer, an accomplished clinician and executive.
- John Kujawa, CTO, directs R&D and design for Osprey catheters.
- Tom Grifa, Senior VP of Operations, with 25+ years in the medical device sector.
- Scott Pease, Senior VP of Regulatory Affairs & QA, expert in global regulatory systems.
- Dave Wirthlin, CFO, co-founder, with a robust finance and operations background.
- Sharon Luboff, Healthcare Advisor, 30+ years in various therapeutic fields.
- David Moss, Marketing Advisor, providing market growth and strategy insights.
Financial Performance and Investments
SkyDance Vascular has raised a total of $5.8 million in seed funding, which includes a recent $3.3 million injection aimed to enhance product development and market reach. The initial seed round amounted to $2.5 million, underscoring a promising startup trajectory.
Vision and Mission
SkyDance Vascular is dedicated to redefining outdated technology and establishing a new standard of care in vascular access. Their mission emphasizes improving clinical outcomes and ensuring clinician safety through transformative healthcare solutions. The leadership team has a track record of previous successful ventures in the vascular access sector, offering substantial potential for growth and investor interest.
Competitor Profiling
Overview
SkyDance operates within a competitive landscape featuring prominent players in the medical devices sector. Key competitors include:
1. Abbott Laboratories: A global healthcare leader with a strong presence in medical devices and pharmaceuticals, operating in over 160 countries with around 114,000 employees.
2. Boston Scientific Corporation: A top-tier medical technology company recognized for high-performance devices and a reach across 127 countries, employing over 53,000 people. In 2024, they dedicated $1.6 billion to R&D and introduced 100 new products, generating $16.7 billion in net sales.
3. Cardinal Health, Inc.: Provides healthcare products and services globally, operating in over 30 countries with approximately 48,000 employees, emphasizing customized solutions for healthcare systems.
4. Other Competitors: Smaller entities like Synergen Technology Labs and IntraFuse compete in similar areas of technology.
Market Position
SkyDance Vascular is strategically positioned against key sector players such as Becton, Dickinson and Company, Siemens Healthineers, and Baxter International. The competitive landscape demands continuous innovation for SkyDance to maintain and expand its market presence.
Recent Developments
SkyDance Vascular's market position is further bolstered through strategic intellectual property acquisitions, including a new U.S. patent announced in November 2021, enriching their competitive edge and product lineup.
